Interleukin-6: a new therapeutic target
The therapeutic success of biological agents, especially the tumour necrosis factor (TNF) inhibitors, has opened a new chapter in the book of therapies for rheumatoid arthritis. Nevertheless, more than 50% of patients may not respond by > 50% improvement. New compounds have recently entered the t...
Main Authors: | , |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2006
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226077/ |